<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="904">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149391</url>
  </required_header>
  <id_info>
    <org_study_id>0702-022</org_study_id>
    <nct_id>NCT05149391</nct_id>
  </id_info>
  <brief_title>A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1 Study of CD19 and CD20 Targeted Chimeric Antigen Receptor T Cells Therapy (C-CAR039) in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in&#xD;
      relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes the following sequential phases: Screening, Apheresis and C-CAR039&#xD;
      manufacturing, Baseline testing, Lymphodepletion, C-CAR039 infusion, Dose-limiting toxicity&#xD;
      observation and Follow-up Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Observation</measure>
    <time_frame>up to 24 Months. Incidence and severity of adverse events after C-CAR039 infusion according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 criteria, including dose-limiting toxicity (DLT) and laboratory abnormalities.</time_frame>
    <description>Incidence of adverse events after C-CAR039 infusion. Incidence and severity of adverse events according to NCI-CTCAE v5.0 criteria, including Dose Limited Toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of C-CAR039 in the peripheral blood.</measure>
    <time_frame>Baseline, Days 4, 7, 10 and weeks 2, 3, 4, 8, 12 and month 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Detect Chimeric Antigen Receptor-T copies number by quantitative polymerase chain reaction(qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) of C-CAR039 in the peripheral blood.</measure>
    <time_frame>Baseline, Days 4, 7, 10 and weeks 2, 3, 4, 8, 12 and month 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Detect Chimeric Antigen Receptor-T copies number by qPCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood duration of C-CAR039 in the peripheral blood after infusion.</measure>
    <time_frame>Baseline, Days 4, 7, 10 and weeks 2, 3, 4, 8, 12 and month 6, 9, 12, 15, 18, 21, 24</time_frame>
    <description>Detect Chimeric Antigen Receptor-T copies number by qPCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve 0h-28d of C-CAR039 in the peripheral blood.</measure>
    <time_frame>Baseline, Days 4, 7, 10 and weeks 2, 3, 4</time_frame>
    <description>Detect Chimeric Antigen Receptor-T copies number by qPCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>4 weeks, 12 weeks, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months</time_frame>
    <description>Complete response (CR) rate plus partial response (PR) rate by Lugano 2014 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The time from the date of first response (PR or better) to the date of disease progression or death after C-CAR039 infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>4 weeks, 12 weeks, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months</time_frame>
    <description>The time from C-CAR039 infusion to the date of progression as assessed by Lugano 2014 criteria or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The time from C-CAR039 infusion to the date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>B Cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CAR039</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous C-CAR039 administered by intravenous (IV) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19/CD20-directed Chimeric Antigen Receptor T Cells</intervention_name>
    <description>Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously</description>
    <arm_group_label>C-CAR039</arm_group_label>
    <other_name>C-CAR039</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient volunteered to participate in the study and signed the Informed Consent;&#xD;
&#xD;
          2. Age, 18-70 years (include 18 and 70), male or female;&#xD;
&#xD;
          3. Expected survival ≥ 12 weeks&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group score 0-2&#xD;
&#xD;
          5. CD19 or CD20 positive B-Non-Hodgkin's lymphoma confirmed by cytology or histology&#xD;
             according to World Health Organization 2016 criteria;&#xD;
&#xD;
          6. Patients with a clear diagnosis of relapsed and/or refractory B-Non-Hodgkin's&#xD;
             lymphoma, including Diffuse Large B Cell Lymphoma, Follicular Lymphoma and Mantle Cell&#xD;
             Lymphoma. Diffuse Large B Cell Lymphoma includes the following types:&#xD;
&#xD;
               1. Diffuse Large B Cell Lymphoma, Non Specifically&#xD;
&#xD;
               2. Primary Mediastinal B-cell Lymphoma&#xD;
&#xD;
               3. Transformed Follicular Lymphoma&#xD;
&#xD;
               4. High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6&#xD;
&#xD;
               5. High Grade B-Cell Lymphoma, Non Specifically&#xD;
&#xD;
          7. For CD20-positive subjects, they should have received at least one regimen containing&#xD;
             anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen&#xD;
             due to intolerance, the cause of intolerance should be recorded;&#xD;
&#xD;
          8. No contraindications of apheresis.&#xD;
&#xD;
          9. At least one measurable lesion according to Lugano 2014 criteria;&#xD;
&#xD;
         10. Adequate organ function and adequate bone marrow reserve&#xD;
&#xD;
               1. Hemoglobin≥80 g/L&#xD;
&#xD;
               2. Absolute neutrophil count≥1.0×109/L&#xD;
&#xD;
               3. Platelet≥50×109/L,&#xD;
&#xD;
               4. Creatinine≤1.5×upper limit of the normal range (ULN)&#xD;
&#xD;
               5. Cardiac ejection fraction≥50%&#xD;
&#xD;
               6. Saturation of Pulse Oxygen&gt;92%&#xD;
&#xD;
               7. Total bilirubin≤1.5×ULN&#xD;
&#xD;
               8. Alanine Aminotransferase/Aspartate Aminotransferase≤3×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Malignant tumors other than B-Non-Hodgkin's lymphoma within 5 years prior to&#xD;
             screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer,&#xD;
             local prostate cancer after radical surgery, and breast ductal carcinoma in situ after&#xD;
             radical surgery;&#xD;
&#xD;
          2. Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus or treponema&#xD;
             pallidum infection ;&#xD;
&#xD;
          3. Any instability of systemic disease, including but not limited to active infection&#xD;
             (except local infection), severe cardiac, liver, kidney, or metabolic disease need&#xD;
             treatment;&#xD;
&#xD;
          4. Female subjects who have been pregnant or breastfeeding, or who plan to conceive&#xD;
             during or within 1 year after treatment, or male subjects' partner plans to conceive&#xD;
             within 1 year after their cell transfusion;&#xD;
&#xD;
          5. Active or uncontrolled infections requiring systemic treatment within 14 days before&#xD;
             enrollment;&#xD;
&#xD;
          6. Patients who have been previously infected with tuberculosis;&#xD;
&#xD;
          7. Administered Corticosteroids and/or other immunosuppressants within 7 days before&#xD;
             apheresis. and 5 days before the infusion of C-CAR039;&#xD;
&#xD;
          8. Patients with central nervous system involvement;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuqin Song, PhD&amp;MD</last_name>
    <phone>010- 88196118</phone>
    <email>SongYQ_VIP@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqin Song, PhD&amp;MD</last_name>
      <phone>010- 88196118</phone>
      <email>SongYQ_VIP@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuqin Song, PhD&amp;MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhitao Ying</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongjing Tang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CD19/CD20-directed Chimeric Antigen Receptor T Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

